ArticleAmerican journal of translational research2021
Analysis of inflammatory factor levels in serum and risk factors in patients with chronic renal failure undergoing maintenance hemodialysis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the therapeutic effect of maintenance hemodialysis in patients with chronic renal failure and summarize the analysis of inflammatory factors in serum, and the risk factors in patients with chronic renal failure undergoing maintenance hemodialysis.
methodsA total of 50 patients with chronic renal failure undergoing maintenance hemodialysis who were admitted to our hospital from January 2017 to January 2019 were selected as the research subjects to analyze the therapeutic effects and complications of maintenance hemodialysis of these patients, compare the changes of inflammatory factor levels in serum such as interleukin-2 (IL-2), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) and renal function indicators such as creatinine, urea nitrogen, and urinary albumin clearance, and analyze the risk factors of maintenance hemodialysis in patients with chronic renal failure by multivariate logistic factor analysis.
resultsThe effective rate of maintenance hemodialysis in patients with chronic renal failure was 64% (32 cases). After dialysis, urea nitrogen, urinary albumin and creatinine clearance were significantly decreased (P < 0.05). As for the complications, 10 patients died, and 8 patients had infection. The levels of inflammatory factors in serum, such as IL-2, hs CRP were significantly decreased after maintenance hemodialysis (P < 0.05), and the difference was statistically significant. The results of multivariate logistic factor analysis showed that high capacity load and anemia were independent risk factors for death in patients with chronic renal failure undergoing maintenance hemodialysis. Simultaneously, diabetes mellitus, central venous catheterization, and hypoalbuminemia were independent risk factors for infection in patients with chronic renal failure undergoing maintenance hemodialysis.
conclusionThe level of inflammatory factors in the serum of patients with chronic renal failure after maintenance hemodialysis was significantly reduced. The risk factors of death and infection include hypertension, anemia, diabetes, etc. In contrast, the independent risk factors of death were anemia and high capacity load, and the independent risk factors of infection were diabetes, hypoalbuminemia, and central venous catheterization.
Indexed as
Identifiers
34306454PMC8290784W3184815903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.